Your browser doesn't support javascript.
loading
Collagenase Clostridium histolyticum Treatment Improves Degree of Curvature in Peyronie's Disease with Calcified Plaques.
Masterson, Thomas A; Atuluru, Pranusha; Zucker, Isaac; Molina, Manuel; Ibrahim, Emad; Nackeeran, Sirpi; Kava, Bruce; Ramasamy, Ranjith.
Affiliation
  • Masterson TA; Desai Sethi Urology Institute, Miller School of Medicine, University of Miami, Miami, FL, USA. Electronic address: TMasterson@med.miami.edu.
  • Atuluru P; Miller School of Medicine, University of Miami, Miami, FL, USA.
  • Zucker I; Desai Sethi Urology Institute, Miller School of Medicine, University of Miami, Miami, FL, USA; Herbert Wertheim School of Medicine, Florida International University, Miami, FL, USA.
  • Molina M; Desai Sethi Urology Institute, Miller School of Medicine, University of Miami, Miami, FL, USA.
  • Ibrahim E; Desai Sethi Urology Institute, Miller School of Medicine, University of Miami, Miami, FL, USA.
  • Nackeeran S; Department of Urology, University of California San Diego, San Diego, CA, USA.
  • Kava B; Desai Sethi Urology Institute, Miller School of Medicine, University of Miami, Miami, FL, USA.
  • Ramasamy R; Desai Sethi Urology Institute, Miller School of Medicine, University of Miami, Miami, FL, USA.
Eur Urol Focus ; 9(1): 55-59, 2023 01.
Article in En | MEDLINE | ID: mdl-36272924
ABSTRACT

BACKGROUND:

Peyronie's disease (PD) is a fibrotic condition of the penis characterized by abnormal plaque formation. Intralesional collagenase Clostridium histolyticum (CCh) is effective in noncalcified PD; however, its effectiveness in calcified PD is not well characterized.

OBJECTIVE:

To assess curvature improvement in calcified PD plaques treated with CCh. DESIGN, SETTING, AND

PARTICIPANTS:

We prospectively evaluated men with calcified PD electing CCh treatment at our institution from October 2018 to November 2020. We assessed curvature with artificial erection and goniometer before and at least 3 mo after treatment. We classified the type of plaque calcification based on ultrasound. INTERVENTION Intralesional CCh. Each treatment cycle consisted of two CCh injections (0.58 mg) into the plaque at the point of maximal penile curvature. The second injection was performed 72 h to 1 wk later, after which participants began modeling. All men were intended to receive a total of eight injections in four cycles, each 6 wk apart. OUTCOME MEASUREMENTS AND STATISTICAL

ANALYSIS:

Change in penile curvature after CCh was measured. We assessed for differences in outcomes based on the number of injections and type of calcification. Unless otherwise specified, data are presented as medians (interquartile range). RESULTS AND

LIMITATIONS:

Sixty men with calcified PD elected CCh; 47 had complete follow-up data. Thirty-nine men completed treatments with eight injections, while the remaining discontinued after a median of five (four to six) injections. There was no difference in response between type 2 and type 3 plaques. Curvature significantly improved by 17.5° (37.5-10.0°) in patients who completed treatment and by 15.0° (20.0-0.0°) in those who discontinued. Limitations include a small sample.

CONCLUSIONS:

Men with calcified PD plaques improve with CCh treatment and show similar improvements regardless of calcification type. PATIENT

SUMMARY:

In this study, we evaluated the efficacy of collagenase Clostridium histolyticum (CCh) treatment in calcified Peyronie's disease (PD) plaques. We found that treatment in calcified plaques demonstrated significant improvement in curvature and the grading of calcification did not impact the degree of curvature improvement. We conclude that participants with calcified PD plaques can benefit from nonsurgical CCh treatment.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Penile Induration Limits: Humans / Male Language: En Journal: Eur Urol Focus Year: 2023 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Penile Induration Limits: Humans / Male Language: En Journal: Eur Urol Focus Year: 2023 Document type: Article